Abstract:Background: Diabetes has been found to increase severity and mortality under the current pandemic of coronavirus disease of 2019 (COVID-19). Up to date, the clinical characteristics of diabetes patients with COVID-19 and the risk factors for poor clinical outcomes are not clearly understood.Methods: The study was retrospectively carried out on enrolled diabetes patients with laboratory confirmed COVID-19 infection from a designated medical center for COVID-19 from January 25th, 2020 to February 14th, 2020 in Wuhan, China. The medical record was collected and reviewed. Univariate and multivariate analyses were performed to assess the risk factors associated with the severe events which were defined as a composite endpoint of admission to intensive care unit, the use of mechanical ventilation, or death.Results: A total of 52 diabetes patients with COVID-19 were finally included in the study. 21 (40.4%) patients had developed severe events in 27.50 (IQR 12.25–35.75) days follow-up, 15 (28.8%) patients experienced life-threatening complications and 8 patients died with a recorded mortality rate of 15.4%. Only 13 patients (41.9%) were in optimal glycemic control with HbA1c value of <7.0%. In addition to general clinical characteristics of COVID-19, the severe events diabetes patients showed higher counts of white blood cells and neutrophil, lower lymphocytes (40, 76.9%), high levels of hs-CRP, erythrocyte sedimentation rate (ESR) and procalcitonin (PCT) as compared to the non-severe diabetes patients. Mild higher level of cardiac troponin I (cTNI) (32.0 pg/ml; IQR 16.80–55.00) and D-dimer (1.70 μg/L, IQR 0.70–2.40) were found in diabetes patients with severe events as compared to the non-severe patients (cTNI:20.00 pg/ml, IQR5.38–30.00, p = 0.019; D-dimer: 0.70 μg/L, IQR 0.30–2.40, p = 0.037). After adjusting age and sex, increased level of cTNI was found to significantly associate with the incidence of severe events (HR: 1.007; 95% CI: 1.000–1.013; p = 0.048), Furthermore, using of α-glucosidase inhibitors was found to be the potential protectant for severe events (HR: 0.227; 95% CI: 0.057–0.904; p = 0.035).Conclusion: Diabetes patients with COVID-19 showed poor clinical outcomes. Vigorous monitoring of cTNI should be recommended for the diabetes patients with COVID-19. Usage of α-glucosidase inhibitors could be a potential protectant for the diabetes patients with COVID-19.

Diabetes is Not Associated with Increased 10-Week Mortality Risk in Patients with Cryptococcal Meningitis

Unique Clinical Features of Cryptococcal Meningitis among Chinese Patients Without Predisposing Diseases Against Patients with Predisposing Diseases

HIV Infection Does Not Increase 10-Week Mortality of Chinese Cryptococcal Meningitis Patients

Unique Cerebrospinal Fluid Profiles of Patients With Human Immunodeficiency Virus- Associated Cryptococcal Meningitis With a Ventriculoperitoneal Shunt : A Retrospective Cohort Study

Clinical Characteristics and Risk Factors for Mortality in Cryptococcal Meningitis: Evidence from a Cohort Study

The clinical profiles and outcomes of HIV-negative cryptococcal meningitis patients in type II diabetes mellitus

The Impact of Diabetes on Mortality in Inpatients from Medical Department of A Chinese Tertiary Hospital

Diabetes Mellitus Type 2 as a Risk Factor and Outcome Modifier for Cryptococcosis in HIV Negative, Non-transplant Patients, a Propensity Score Match Analysis

A 12-Year Single-Center Experience in China

Clinical Features and Outcomes of Cryptococcemia Patients with and Without HIV Infection

The risk factors for mortality of diabetic patients with severe COVID-19: A retrospective study of 167 severe COVID-19 cases in Wuhan

Analysis of the Relationship Between Drug Susceptibility of Cryptococcus Neoformans Isolates and Mortality in HIV-negative Cryptococcal Meningitis

The Impact of Blood Glucose Level on the Clinical Outcomes of Patients Hospitalized with Community-Acquired Pneumonia: A Multicenter, Retrospective Study

Does Diabetes Mellitus Increase the Short- and Long-Term Mortality in Patients With Critical Acute Myocardial Infarction? Results From American MIMIC-III and Chinese CIN Cohorts

Glucocorticoids as a risk factor for infection and adverse outcomes in non‐HIV and non‐transplant patients with cryptococcal meningitis

Clinical characteristics and prognostic factors of 60 patients with acquired immune deficiency syndrome combined with Cryptococcus neoformans

Anti-GM-CSF autoantibodies predict outcome of cryptococcal meningitis in patients not infected with HIV: A cohort study

Clinical Features and Treatment Outcomes of Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: a 2-Year Retrospective Analysis

Risk Factors for Poor Outcomes of Diabetes Patients With COVID-19: A Single-Center, Retrospective Study in Early Outbreak in China

Cryptococcal Meningitis in Non-Hiv-infected Patients in a Chinese Tertiary Care Hospital, 1997-2007.

Comprehensive comparison of clinicoradiological, laboratory, and prognostic factors of community-acquired pneumonia in diabetic and nondiabetic hospitalized patients